Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
Adolescent
Adult
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
Child
Child, Preschool
Drug Resistance, Neoplasm
/ drug effects
Female
Humans
Inotuzumab Ozogamicin
Male
Neoplasm Recurrence, Local
/ drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Prognosis
Remission Induction
Retrospective Studies
Salvage Therapy
Survival Rate
Young Adult
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
03
06
2018
accepted:
16
08
2018
revised:
09
08
2018
pubmed:
30
9
2018
medline:
10
8
2019
entrez:
30
9
2018
Statut:
ppublish
Résumé
Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/refractory ALL treated in the compassionate use program. In this heavily pretreated cohort, complete remission was achieved in 67% of patients with overt marrow disease. The majority (71%) of responders were negative for minimal residual disease. Responses were observed irrespective of cytogenetic subtype or number or type of prior treatment regimens. InO was well-tolerated; grade 3 hepatic transaminitis or hyperbilirubinemia were noted in 6 (12%) and grade 3/4 infections in 11 (22%) patients. No patient developed sinusoidal obstruction syndrome (SOS) during InO therapy; however, 11 of 21 (52%) patients who underwent hematopoietic stem cell transplantation (HSCT) following InO developed SOS. Downregulation of surface CD22 was detected as a possible escape mechanism in three patients who developed a subsequent relapse after InO. We conclude that InO is a well-tolerated, effective therapy for children with relapsed ALL and prospective studies are warranted. Identification of risk factors for developing post-HSCT SOS and strategies to mitigate this risk are ongoing.
Identifiants
pubmed: 30267011
doi: 10.1038/s41375-018-0265-z
pii: 10.1038/s41375-018-0265-z
pmc: PMC6438769
mid: NIHMS1504105
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents
0
Inotuzumab Ozogamicin
P93RUU11P7
Types de publication
Journal Article
Langues
eng
Pagination
884-892Subventions
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Organisme : NULL
ID : Z99 CA999999
Pays : International
Commentaires et corrections
Type : ErratumIn
Références
Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013;14:e205–17.
doi: 10.1016/S1470-2045(12)70580-6
Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018. https://doi.org/10.1038/s41375-018-0094-0 . [Epub ahead of print].
doi: 10.1038/s41375-018-0094-0
Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010;28:648–54.
doi: 10.1200/JCO.2009.22.2950
Dahl J, Marx K, Jabbour E. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Rev Hematol. 2016;9:329–34.
doi: 10.1586/17474086.2016.1143771
Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol. 2005;88:1–50.
doi: 10.1016/S0065-2776(05)88001-0
Shah NN, Stevenson MS, Yuan CM, Richards K, Delbrook C, Kreitman RJ, et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:964–9.
doi: 10.1002/pbc.25410
DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1:1167–80.
doi: 10.1182/bloodadvances.2016001925
Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403–11.
doi: 10.1016/S1470-2045(11)70386-2
Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–53.
doi: 10.1056/NEJMoa1509277
Lamb YN. Inotuzumab ozogamicin: first global approval. Drugs. 2017;77:1603–10.
doi: 10.1007/s40265-017-0802-5
Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578–82.
doi: 10.1182/blood-2003-01-0255
Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4:e387–e98.
doi: 10.1016/S2352-3026(17)30103-5
Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, et al. Salvage chemoimmunotherapy with inotuzumab oogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4:230–4.
doi: 10.1001/jamaoncol.2017.2380
Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19:240–8.
doi: 10.1016/S1470-2045(18)30011-1
Rytting M, Triche L, Thomas D, O’Brien S, Kantarjian H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61:369–72.
doi: 10.1002/pbc.24721
Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–95.
doi: 10.1158/2159-8290.CD-15-1020
Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134–40.
doi: 10.1200/JCO.2014.56.3247
Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118:6043–9.
doi: 10.1182/blood-2011-08-374710
Sun W, Orgel E, Malvar J, Sposto R, Wilkes JJ, Gardner R, et al. Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63:1943–8.
doi: 10.1002/pbc.26129
Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 2010;148:768–76.
doi: 10.1111/j.1365-2141.2009.08011.x